Monopar Therapeutics (NASDAQ:MNPR) Releases Quarterly Earnings Results, Beats Estimates By $0.10 EPS

Key Points

• Monopar Therapeutics reported a quarterly loss of $0.72 per share, beating analyst estimates of a $0.82 loss by $0.10.
• Analyst sentiment was mixed but leaned positive: seven analysts rated the stock Buy, one Hold and one Sell; the consensus rating was Moderate Buy with a $122.78 target price.
• Company insiders sold 51,920 shares worth about $4.53 million over the past 90 days. Shares traded at $73.06 on Thursday, up 1.9%.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.72) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.82) by $0.10, FiscalAI reports.

Monopar Therapeutics Trading Up 1.9%

Shares of MNPR traded up $1.33 during trading hours on Thursday, reaching $73.06. 217,522 shares of the stock traded hands, compared to its average volume of 202,799. Monopar Therapeutics has a 52-week low of $50.07 and a 52-week high of $124.82. The company's 50-day moving average price is $84.40 and its two-hundred day moving average price is $77.39. The company has a market cap of $490.38 million, a P/E ratio of -33.64 and a beta of 1.62.

Wall Street Analyst Weigh In

Several research firms recently weighed in on MNPR. BTIG Research lifted their target price on Monopar Therapeutics from $117.00 to $133.00 and gave the company a "buy" rating in a research report on Wednesday, August 12th. Weiss Ratings reissued a "sell (d-)" rating on shares of Monopar Therapeutics in a report on Thursday, October 15th. Wall Street Zen cut Monopar Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, October 10th. UBS Group set a $125.00 price objective on Monopar Therapeutics in a research note on Thursday, July 23rd. Finally, HC Wainwright boosted their price objective on Monopar Therapeutics from $105.00 to $125.00 and gave the company a "buy" rating in a research note on Wednesday, July 22nd. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $122.78.

Insider Activity

In other Monopar Therapeutics news, Director Christopher Starr sold 8,400 shares of the firm's stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $78.50, for a total transaction of $659,400.00. Following the sale, the director directly owned 5,173 shares of the company's stock, valued at $406,080.50. This trade represents a 61.89% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kim Tsuchimoto sold 4,090 shares of the firm's stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $111.39, for a total value of $455,585.10. Following the sale, the director directly owned 7,396 shares in the company, valued at approximately $823,840.44. This represents a 35.61% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 51,920 shares of company stock worth $4,527,913. 9.70% of the stock is currently owned by corporate insiders.

About Monopar Therapeutics

Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. Its pipeline includes radiopharmaceutical candidates designed to target the urokinase plasminogen activator receptor (uPAR), a protein found at elevated levels in some cancers. The company is developing MNPR-101-Zr as an imaging agent to identify uPAR-expressing tumors and MNPR-101-Lu as a potential targeted radiation therapy. These candidates are investigational and are not approved for commercial use.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.